IP Library › Granted Patent US 12,440,446
Granted Patent B2
US 12,440,446 · App. 18/049,519 · Granted Oct 14, 2025

Polymeric delivery systems

Inventors: Jeremy J. Harris (Doylestown, PA); Scott Radzinski (Gilbertsville, PA); Brian Ginn (Harleysville, PA); Peter D. Gabriele (Frisco, TX); Benjamin Roadarmel (Quakertown, PA)
Assignee: THE SECANT GROUP, LLC
A61K9/1647A61K9/5026A61K9/5146A61K31/7105A61K31/711A61K47/34B82Y5/00C08F120/60A61K48/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,440,446
App. No.
18/049,519
Granted
Oct 14, 2025
Kind
B2
Abstract

A polymeric delivery system delivers a biologic to cells. In some embodiments, the polymeric delivery system includes polyplexes. Each polyplex includes at least one charged polymer and at least one biologic. The at least one charged polymer includes a polyester copolymer of a polyol and a polycarboxylic acid modified with at least one charged moiety having an opposite charge from a net charge of the at least one biologic. In other embodiments, the polymeric delivery system includes self-assembled particles including a block copolymer and a biologic associated with the block copolymer. The block copolymer includes a first block of a polyester copolymer of a polyol and a polycarboxylic acid and a second block of a second monomer or a second polymer.

Claims (25)

1. A polymeric delivery system comprising polyplexes comprising at least one charged polymer and at least one biologic, wherein the at least one charged polymer comprises a polyester copolymer of alternating monomers of a polyol monomer and a polycarboxylic acid monomer, wherein the polyol monomer comprises glycerol and wherein the polyester copolymer of alternating monomers of a polyol monomer and a polycarboxylic acid monomer has been modified by derivatization of at least a portion of free alcohols of the glycerol to incorporate at least one charged moiety having an opposite charge from a net charge of the at least one biologic, wherein the at least one charged moiety is selected from the group consisting of glutamine, lysine, arginine, sulfate, phosphate, sulfonate, sulfite, carboxy salt, ammonium, choline, phosphocholine, primary amine, secondary amine, tertiary amine, quaternary amine, and carboxylate.

2. The polymeric delivery system of claim 1 , wherein the polyplexes have a number-weighted average particle size in the range of about 10 nm to about 1000 nm.

3. The polymeric delivery system of claim 1 further comprising a solvent.

4. The polymeric delivery system of claim 1 , wherein the polycarboxylic acid monomer is selected from the group consisting of sebacic acid, succinic acid, and a combination thereof.

5. The polymeric delivery system of claim 1 , wherein the at least one charged polymer and the at least one biologic are associated by ligand interaction or complex coordination.

6. The polymeric delivery system of claim 1 , wherein the at least one biologic is selected from the group consisting of a nucleic acid, an amino acid, a peptide, a protein, a gene editing system, an antibody, and a cytokine.

7. The polymeric delivery system of claim 6 , wherein the at least one biologic comprises a nucleic acid.

8. The polymeric delivery system of claim 1 , wherein the at least one charged polymer is non-immunogenic.

9. The polymeric delivery system of claim 1 further comprising an additive selected from the group consisting of a salt, a buffer, a surfactant, a stabilizing agent, and a combination thereof, wherein the additive tunes at least one property of the polyplexes.

10. A process of forming a polymeric delivery system comprising polyplexes, the process comprising combining charged polymers and biologics in a solvent to associate the charged polymers and the biologics as the polyplexes, the polyplexes comprising at least one of the charged polymers and at least one of the biologics, wherein the polyol monomer comprises glycerol and wherein each of the charged polymers comprises a polyester copolymer of alternating monomers of a polyol monomer and a polycarboxylic acid monomer, wherein the polyester copolymer of alternating monomers of a polyol monomer and a polycarboxylic acid monomer has been modified by derivatization of at least a portion of free alcohols of the glycerol to incorporate at least one charged moiety having an opposite charge from a net charge of the biologics, wherein the at least one charged moiety is selected from the group consisting of glutamine, lysine, arginine, sulfate, phosphate, sulfonate, sulfite, carboxy salt, ammonium, choline, phosphocholine, primary amine, secondary amine, tertiary amine, quaternary amine, and carboxylate.

11. The process of claim 10 , wherein the polyplexes have a number-weighted average particle size in the range of about 10 nm to about 1000 nm.

12. The process of claim 10 , wherein the polycarboxylic acid monomer is selected from the group consisting of sebacic acid, succinic acid, and a combination thereof.

13. The process of claim 10 further comprising modifying the polyester copolymer of alternating monomers of a polyol monomer and a polycarboxylic acid monomer with the at least one charged moiety to form the charged polymers.

14. The process of claim 10 , wherein the biologics are selected from the group consisting of a nucleic acid, an amino acid, a peptide, a protein, a gene editing system, an antibody, and a cytokine.

15. The process of claim 14 , wherein the biologics comprise a nucleic acid.

16. The process of claim 10 further comprising adding at least one additive to the polymeric delivery system, wherein the additive is selected from the group consisting of a salt, a buffer, a surfactant, a stabilizing agent, and a combination thereof.

17. A process of delivering a biologic to cells, the process comprising administering polyplexes of the biologic associated with a charged polymer, the charged polymer comprising a polyester copolymer of alternating monomers of a polyol monomer and a polycarboxylic acid monomer, wherein the polyol monomer comprises glycerol and wherein the polyester copolymer of alternating monomers of a polyol monomer and a polycarboxylic acid monomer has been modified by derivatization of at least a portion of free alcohols of the glycerol to incorporate at least one charged moiety having an opposite charge from a net charge of the biologic, wherein the at least one charged moiety is selected from the group consisting of glutamine, lysine, arginine, sulfate, phosphate, sulfonate, sulfite, carboxy salt, ammonium, choline, phosphocholine, primary amine, secondary amine, tertiary amine, quaternary amine, and carboxylate.

18. The process of claim 17 , wherein the polyplexes have a number-weighted average particle size in the range of about 10 nm to about 1000 nm.

19. The process of claim 17 , wherein the administering comprises administering to the cells ex vivo.

20. The process of claim 17 , wherein the administering comprises administering to the cells in vitro.

21. The process of claim 17 , wherein the administering comprises administering to the cells in vivo.

22. The process of claim 17 further comprising combining the charged polymer and the biologic to form the polyplexes.

23. The process of claim 17 , wherein the polycarboxylic acid monomer is selected from the group consisting of sebacic acid, succinic acid, and a combination thereof.

24. The process of claim 17 , wherein the biologic is selected from the group consisting of a nucleic acid, an amino acid, a peptide, a protein, a gene editing system, an antibody, and a cytokine.

25. The process of claim 24 , wherein the biologic comprises a nucleic acid.

Assignments (2)
SECURITY INTEREST Recorded Jun 20, 2025
From: THE SECANT GROUP, LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 071473/0287 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2022
From: HARRIS, JEREMY J.; RADZINSKI, SCOTT; GINN, BRIAN; GABRIELE, PETER D.; ROADARMEL, BENJAMIN
To: THE SECANT GROUP, LLC
Reel/Frame 061705/0224 →
Continuity (3)
Provisional Application 63271283 · Oct 25, 2021
Provisional Application 63271275 · Oct 25, 2021
Related Publication 20230125499A1 · Apr 27, 2023
References Cited (30)
US 6890560B2 · Seo · 2005 [cited by examiner]
US 9359472B2 · Nicholson et al. · 2016 [cited by applicant]
US 10619162B1 · Rossi · 2020 [cited by applicant]
US 20110256227A1 · Mirosevich · 2011 [cited by examiner]
US 20190328677A1 · Kim et al. · 2019 [cited by applicant]
US 20210220287A1 · Jamieson et al. · 2021 [cited by applicant]
US 20210236645A1 · Li et al. · 2021 [cited by applicant]
US 20210239347A1 · Wiens-Kind et al. · 2021 [cited by applicant]
JP 2018145155A · 2018 [cited by applicant]
WO WO2007001448A2 · 2007 [cited by examiner]
WO 2021023798A1 · 2021 [cited by applicant]
Louage et al. “Poly(glycerol sebacate) nanoparticles for encapsulation of hydrophobic anti-cancer drugs” Polym. Chem. 2017, 8, 5033-5038. (Year: 2017). [cited by examiner]
Gaucher et al. “Block copolymer micelles: preparation, characterization and application in drug delivery” Journal of Controlled Release 2005, 109, 169-188. (Year: 2005). [cited by examiner]
Chen et al. “Biodegradable Polymers for Gene-Delivery Applications”, International Journal of Nanomedicine, 2020, 15, 2131-2150. (Year: 2020). [cited by examiner]
Loh et al. “Poly(glycerol sebacate) biomaterial: synthesis and biomedical applications” J. Mater. Chem. B, 2015, 3, 7641-7652. (Year: 2015). [cited by examiner]
Desai et al. “Self-assembled, ellipsoidal polymeric nanoparticles for intracellular deliver of therapeutics” Journal of Biomedical Materials Research A 2018, 106A, 2048-2058. (Year: 2018). [cited by examiner]
Zugates et al. “Gene Delivery Properties of End-Modified Poly(B-amino ester)s” Bioconjugate Chem. 2007, 18, 1887-1896) (Year: 2007). [cited by examiner]
Altman et al., “From Krebs to Clinic: Glutamine Metabolism to Cancer Therapy”, Nat. Rev. Cancer, vol. 16, pp. 619-634 (2016). [cited by applicant]
Hou et al., “Lipid nanoparticles for mRNA delivery”, Nature Review Materials, vol. 6, pp. 1078-1094 (2021). [cited by applicant]
Mitchell et al., “Engineering precision nanoparticles for drug delivery”, Nature Reviews: Drug Discovery, vol. 20, pp. 101-124, (2021). [cited by applicant]
Yang et al., “Glutamine Oxidation Maintains the TCA Cycle and Cell Survival during Impaired Mitochondrial Pyruvate Transport”, Molecular Cell, vol. 56, pp. 414-424 (2014). [cited by applicant]
Chen et al., “Biodegradable Polymers for Gene-Delivery Applications”, International Journal of Nanomedicine, vol. 15, Mar. 1, 2020, pp. 2131-2150. [cited by applicant]
Desai et al., “Self-assembled, ellipsodal polymeric nanoparticles for intracellular delivery of therapeutics”, Journal of Biomed. Materials Research Part A, vol. 106A, No. 7, Apr. 30, 2018, pp. 2048-2058. [cited by applicant]
Loh et al., “Poly(glycerol sebacate) biomaterial: synthesis and biomedical applications”, Journal of Materials Chemistry B, vol. 3, No. 39, Jan. 1, 2015, pp. 7641-7652. [cited by applicant]
Louage et al., “Poly(glycerol Sebacate) nanoparticles for encapsulation of hydrophobic anti-cancer drugs”, Polymer Chemistry, vol. 8, No. 34, Jan. 1, 2017, pp. 5033-5038. [cited by applicant]
Dueno et al., “Cesium Promoted O-Alkylation of Alcohols for the Efficient Ether Synthesis”, Tetrahedron Letters, vol. 40, pp. 1843-1846 (1999). [cited by applicant]
Syga et al., “Albumin Incorporation in Polyethylenimine-DNA Polyplexes Influences Transfection Efficacy”, Biomacromolecules, vol. 17, pp. 200-207 (2016). [cited by applicant]
Zhang et al., “Polymersomes in Nanomedicine—A Review”, Current Nanoscience, vol. 13, pp. 124-129 (2019). [cited by applicant]
Wang et al., “Poly(Glycerol Sebacate) in Tissue Engineering and Regenerative Medicine”, Material Matters, 13 pages, (2016). [cited by applicant]
Kamijo et al., “An Improved and Convenient Synthesis of Esters Using 1,1′-Carbonyldiimidazole and a Reactive Halide”, Chem. Pharm. Bull., vol. 32, pp. 5044-5047, (1984). [cited by applicant]